More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says
More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved for Crohn’s disease
Subscribe or to access all post and page content.